Paper41454396
Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.
Fatahichegeni M and 5 others. J Transl Med, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. Papers, record 41454396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41454396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neurotoxicity Syndromes | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Animals |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| National Key R&D Program, Grant/Award Number: 2022YFC2502700 | National Key R&D Program, Grant/Award Number: 2022YFC2502700 | PubMed |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36531846 | Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. | Neurohospitalist | 2023 | https://conductscience.org/library/papers/36531846 | PubMed |
| 2 | 38300610 | Two years later: CD19 CAR-T going the distance. | Blood | 2024 | https://conductscience.org/library/papers/38300610 | PubMed |
| 3 | 40650909 | CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. | Cell Rep | 2025 | https://conductscience.org/library/papers/40650909 | PubMed |
| 4 | 36860569 | A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. | Front Neurol | 2023 | https://conductscience.org/library/papers/36860569 | PubMed |
| 5 | 36593069 | CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/36593069 | PubMed |
| 6 | 33985527 | Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. | Cancer Cell Int | 2021 | https://conductscience.org/library/papers/33985527 | PubMed |
| 7 | 33599849 | Correction to: ICU-outcomes in CAR-T patients-A single centre experience. | Intensive Care Med Exp | 2021 | https://conductscience.org/library/papers/33599849 | PubMed |
| 8 | 38203814 | The Mechanisms of Altered Blood-Brain Barrier Permeability in CD19 CAR T-Cell Recipients. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38203814 | PubMed |
| 9 | 36989488 | How I treat refractory CRS and ICANS after CAR T-cell therapy. | Blood | 2023 | https://conductscience.org/library/papers/36989488 | PubMed |
| 10 | 37345104 | Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345104 | PubMed |
| 11 | 32327504 | Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. | Haematologica | 2021 | https://conductscience.org/library/papers/32327504 | PubMed |
| 12 | 36414694 | EEG-based grading of immune effector cell-associated neurotoxicity syndrome. | Sci Rep | 2022 | https://conductscience.org/library/papers/36414694 | PubMed |
| 13 | 39567446 | Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model. | EJNMMI Res | 2024 | https://conductscience.org/library/papers/39567446 | PubMed |
| 14 | 36763238 | CAR-T Cell Therapy: the Efficacy and Toxicity Balance. | Curr Hematol Malig Rep | 2023 | https://conductscience.org/library/papers/36763238 | PubMed |
| 15 | 35216966 | Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. | Med Intensiva (Engl Ed) | 2022 | https://conductscience.org/library/papers/35216966 | PubMed |
| 16 | 32271898 | Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. | Blood Adv | 2020 | https://conductscience.org/library/papers/32271898 | PubMed |
| 17 | 35094839 | [Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]. | Bull Cancer | 2023 | https://conductscience.org/library/papers/35094839 | PubMed |
| 18 | 39474369 | Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis. | Front Neurol | 2024 | https://conductscience.org/library/papers/39474369 | PubMed |
| 19 | 35000613 | Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. | Neurol Res Pract | 2022 | https://conductscience.org/library/papers/35000613 | PubMed |
| 20 | 34794490 | Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34794490 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953552 | Neurologist-focused workflows for immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy and CD3-engaging bispecific antibodies. | Front Neurol | 2026 | https://conductscience.org/library/papers/42953552 | PubMed |
| 42921052 | When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921052 | PubMed |
| 42865900 | B7-H3-mediated immune regulation in cancer: biological functions and therapeutic opportunities. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42865900 | PubMed |
| 42840927 | Microbiota-derived metabolic priming of CAR-T cell fitness: a translational framework for next-generation cell therapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42840927 | PubMed |
| 42592017 | Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway. | TH Open | 2026 | https://conductscience.org/library/papers/42592017 | PubMed |
| 42590834 | Targeted delivery of mRNA to immune cells for in vivo cell therapy. | Drug Deliv | 2026 | https://conductscience.org/library/papers/42590834 | PubMed |
| 42548674 | Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42548674 | PubMed |
| 42345736 | Quality of Life in CAR-T Cell Therapy. | Hematol Rep | 2026 | https://conductscience.org/library/papers/42345736 | PubMed |
| 42286319 | Reprogramming immunity: the promise and challenges of CAR T cell therapy in multiple sclerosis. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/42286319 | PubMed |
| 42109668 | Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42109668 | PubMed |
| 42108277 | T-Cell Immunosenescence in Systemic Lupus Erythematosus: Molecular Mechanisms and Therapeutic Perspectives. | Clin Rev Allergy Immunol | 2026 | https://conductscience.org/library/papers/42108277 | PubMed |
| 41928252 | In vivo CAR-T therapy: from molecular design to precision delivery. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41928252 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41454396
GET https://conductscience.org/api/papers/v1/41454396/references?page=2